Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Toyama Chemical Applies for Anti-flu Drug T-750
April 11, 2011
- Full Operations Still on Hold at Utsunomiya Plant: Chugai
April 11, 2011
- Simultaneous Vaccination with 2 Vaccines Resumed from April 1
April 11, 2011
- FDA Approves Long-acting Treatment for OA Knee Pain: Seikagaku
April 11, 2011
- Korosho Asks METI to Exclude Drug Production Facilities from Planned Electricity Outages
April 11, 2011
- NICE Recommends Aricept for Mild AD
April 11, 2011
- Seikagaku Withdraws PMA for Additional Indication of Supartz in the US
April 11, 2011
- Earthquake Disrupts Production of Some Raw Materials
April 11, 2011
- PMAT, OPMA Petition MREAC on Pass/Fail Criteria for MR Exam
April 11, 2011
- Korosho Requires Revision of Package Insert for Hib Vaccine, Pneumococcal Vaccines
April 11, 2011
- Production, Shipment of Sublood to Resume in Mid-April: Fuso
April 11, 2011
- RAD-AR Completes Patient Database on Antihyperlipidemics
April 11, 2011
- Gov't-Private Sector Dialogue Postponed due to Earthquake
April 11, 2011
- MTPC Aims to Resume Operations at 2 Plants in Mid-April
April 11, 2011
- ProStrakan Shareholders Accept Acquisition by Kyowa Kirin
April 11, 2011
- Shionogi Signs Agreement with Denmark on Industry-Academic Collaboration
April 11, 2011
- Some Companies Postpone April Personnel Changes due to Earthquake
April 11, 2011
- Abbott Japan Completes Acquisition of Former Solvay Pharm.
April 11, 2011
- OncoTherapy Starts PII Trial of Angiogenesis Inhibitor
April 11, 2011
- Eisai Licenses Bexarotene to Minophagen
April 11, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…